Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct 29;4(4):1146-60.
doi: 10.3390/cancers4041146.

Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction

Affiliations

Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction

Rakhshanda Layeequr Rahman et al. Cancers (Basel). .

Abstract

Women who are at high risk of breast cancer can be offered chemoprevention. Chemoprevention strategies have expanded over the past decade and include selective receptor modulator inhibitors and aromatase inhibitors. Physicians are expected to provide individualized risk assessments to identify high risk women who may be eligible for chemoprevention. It is prudent that physicians utilize a shared decision approach when counseling high risk women about their preventive options. Barriers and misperceptions however exist with patient and physician acceptance of chemoprevention and continue to impede uptake of chemoprevention as a strategy to reduce breast cancer risk. Programs to increase awareness and elucidate the barriers are critical for women to engage in cancer prevention and promote chemoprevention adherence.

PubMed Disclaimer

References

    1. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 1998;90:1371–1388. doi: 10.1093/jnci/90.18.1371. - DOI - PubMed
    1. DeSantis C., Howlader N., Cronin K.A., Jemal A. Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol. Biomarkers Prev. 2011;20:733–739. doi: 10.1158/1055-9965.EPI-11-0061. - DOI - PubMed
    1. DeSantis C., Siegel R., Bandi P., Jemal A. Breast cancer statistics, 2011. CA Cancer J. Clin. 2011;61:409–418. - PubMed
    1. Cuzick J., Powles T., Veronesi U., Forbes J., Edwards R., Ashley S., Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296–300. - PubMed
    1. Visvanathan K., Chlebowski R.T., Hurley P., Col N.F., Ropka M., Collyar D., Morrow M., Runowicz C., Pritchard K.I., Hagerty K., et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J. Clin. Oncol. 2009;27:3235–3258. - PMC - PubMed